NeuroPace Inc (NPCE)
13.69
-0.31
(-2.21%)
USD |
NASDAQ |
Apr 19, 16:00
13.69
0.00 (0.00%)
After-Hours: 16:04
NeuroPace Cash from Financing (TTM): 8.127M for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | 8.127M |
| September 30, 2023 | -0.225M |
| June 30, 2023 | -0.206M |
| March 31, 2023 | 0.234M |
| December 31, 2022 | 0.49M |
| September 30, 2022 | 1.539M |
| June 30, 2022 | 1.547M |
| Date | Value |
|---|---|
| March 31, 2022 | 104.10M |
| December 31, 2021 | 102.53M |
| September 30, 2021 | 101.34M |
| June 30, 2021 | 140.15M |
| March 31, 2021 | 40.91M |
| December 31, 2020 | 55.01M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
-0.225M
Minimum
Sep 2023
140.15M
Maximum
Jun 2021
42.73M
Average
8.127M
Median
Dec 2023
Cash from Financing (TTM) Benchmarks
| Ainos Inc | 4.924M |
| OpGen Inc | 7.287M |
| Zomedica Corp | -- |
| LENSAR Inc | -- |
| Eargo Inc (DELISTED) | 33.86M |